ESEun Mi Song

Eun Mi Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eun Mi Song has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disease characteristics, outcomes, and poor prognostic factors of perianal fistula in Korean patients with Crohn’s disease: a multicenter, retrospective observational study

    by Hyuk Yoon, Sang Bum Kang, Seong-Joon Koh, Chang Kyun Lee, Dongwoo Kim, Eun Soo Kim, Sung Noh Hong, Dong Hyun Kim, Jin Wook Lee, Soo Jung Park, et al.

    Disease characteristics, outcomes, and poor prognostic factors of perianal fistula in Korean patients with Crohn’s disease: a multicenter, retrospective observational study

  • Open Access

    Venous thromboembolism prophylaxis in pregnant women with inflammatory bowel disease: evidence gaps and future directions from the KASID Guidelines Task Force Team

    by Jiyoung Yoon, Eun Mi Song, Dong Hyun Kim, Young Joo Yang, Seung Yong Shin, Ji Eun Kim, June Hwa Bae, Seung Min Hong, Sang-Bum Kang, Eun Soo Kim, et al.

    Venous thromboembolism (VTE) is a serious and potentially life-threatening complication in patients with inflammatory bowel disease (IBD), with the risk further increased during pregnancy and the postpartum period. Pregnancy induces a physiological hypercoagulable state, which, when combined with the chronic inflammatory and prothrombotic milieu of IBD, may result in synergistic thrombotic risk. Population-based cohort studies and meta-analyses consistently demonstrate an elevated risk of VTE during pregnancy and the postpartum period among women with IBD compared with those without, with risk being further amplified by active disease, hospitalization, or cesarean delivery. Current gastroenterology and obstetric guidelines recommend selective, risk-stratified thromboprophylaxis rather than routine anticoagulation for all pregnant women with IBD, emphasizing individualized assessment based on disease activity and additional obstetric risk factors. However, the majority of available evidence and current guideline recommendations are based predominantly on data from Western populations. Although the relative risk of VTE appears broadly comparable across ethnicities, Asian populations demonstrate substantially lower absolute incidence rates and distinct obstetric practice patterns, raising concerns regarding the direct applicability of Western guidelines. This narrative review summarizes the current evidence on the risk of VTE associated with pregnancy and the postpartum period in women with IBD and systematically examines existing thromboprophylaxis recommendations and safety considerations. Consequently, it identifies key clinical variables and analytical perspectives relevant to Asian populations that should be addressed in future research and aims to facilitate the development of population-specific, risk-based thromboprophylaxis strategies that balance the benefits and risks of anticoagulation.

  • Open Access

    Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations

    by Eun Soo Kim, Dong Hyun Kim, Seong-Jung Kim, Sang Hyoung Park, Hyun Seok Lee, Sung Kook Kim, Hyun Soo Kim, Jun Lee, Kyeong Ok Kim, Byung Ik Jang, et al.

    Background: This study aimed to develop predictive models for acute severe ulcerative colitis (ASUC) using data from East Asian (EA) patients and to validate their performance in an Australia/New Zealand (ANZ) cohort. Methods: A retrospective international study was conducted across 23 referral hospitals in EA and ANZ, enrolling consecutive ASUC patients between January 2015 and December 2022. Logistic regression analyses were used to construct predictive models for 1-year colectomy and non-response to corticosteroid therapy (NRS). Results: Overall, 826 patients with ASUC were included (411 EA and 415 ANZ). Among EA patients, independent predictors of 1-year colectomy included female sex, prior exposure to tumor necrosis factor inhibitors, and admission albumin ≤3 g/dL. Independent predictors of NRS in the EA cohort were age at diagnosis ≤37 years, baseline steroid use, admission albumin ≤2.5 g/dL, and the presence of extraintestinal manifestations. The EA-derived scoring systems demonstrated strong predictive performance within the EA cohort (1-year colectomy: P < .0001; NRS: P = .001) but showed limited utility in the ANZ cohort (P = .106 and P = .012). In contrast, European-developed models—including the French 1-year colectomy score and the ADMIT-ASC index for NRS—accurately predicted outcomes in the ANZ cohort (P = .007 and P < .0001) but had reduced predictive capacity in the EA cohort (P = .106 and P = .026). These findings were consistent in both cohorts following propensity score matching. Conclusions: Predictive factors for ASUC differ substantially between EA and ANZ patients, highlighting the need for population-specific predictive tools.

  • Open Access

    Practices and perceptions of imaging assessment in inflammatory bowel disease: a nationwide survey of physicians in Korea by the KASID Guidelines Taskforce Team

    by Ji Eun Kim, Young Joo Yang, June Hwa Bae, Seung Yong Shin, Dong Hyun Kim, Seung Min Hong, Eun Mi Song, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, et al.

    Background/Aims: Imaging-based assessment is essential for evaluating disease activity and structural damage in inflammatory bowel disease (IBD). This study aimed to evaluate real-world use and perceptions of imaging modalities among Korean IBD experts and to identify implications for future domestic guideline development. Methods: A nationwide, web-based survey was conducted among board-certified gastroenterologists affiliated with the Korean Association for the Study of Intestinal Diseases. The questionnaire assessed respondent characteristics, imaging modality use in Crohn’s disease (CD) and ulcerative colitis (UC), and perceptions of clinical utility using a 5-point Likert scale. Results were summarized as frequencies and percentages.Results: Of 150 invited clinicians, 133 responded, with 74.4% practicing in tertiary referral centers. In CD, computed tomography enterography (CTE) and magnetic resonance enterography (MRE) were the most used modalities at diagnosis and follow-up. In contrast, IUS utilization was low (6.8% at diagnosis and 10.5% during follow-up), and 82.0% reported no intestinal ultrasound (IUS) use in the preceding year. In UC, CT-based strategies also predominated, and more than half reported no imaging during follow-up. Major barriers to IUS adoption included limited experience, time constraints, and institutional or equipment limitations. CT/CTE and MRE were perceived as useful for diagnosis and complication assessment, whereas IUS was viewed as suitable for repeated monitoring but highly operator dependent. Conclusions: IBD imaging practices in Korea rely predominantly on CT-based modalities, with limited real-world use of MRE and IUS despite their recognized clinical potential. Future Korean guidelines should acknowledge these real-world limitations while encouraging gradual integration of MRE and IUS.


  • Open Access

    Endoscopic vacuum therapy for gastrointestinal transmural defects: clinical outcomes and treatment implications: a retrospective study from Korea

    by A Reum Choe, Ki-Nam Shim, Ju-Ran Byeon, Yehyun Park, Eun Mi Song, Chung Hyun Tae, Sung-Ae Jung

    Purpose: Endoscopic vacuum therapy (EVT) has emerged as a highly effective approach for managing gastrointestinal transmural defects and may offer advantages over traditional methods, such as stenting. This study evaluated the clinical outcomes of EVT for gastrointestinal transmural defects resulting from leakages, perforations, and fistulas.Methods: We retrospectively reviewed patients who underwent EVT for gastrointestinal transmural defects at Ewha Womans University Medical Center between February 2018 and September 2025 and analyzed clinical outcomes, adverse events, and risk factors associated with adverse events.Results: Fourteen patients were included (mean age, 63.9 years; 85.7% male). Stomach surgery was the most common etiology (50.0%), and malignancy accounted for 71.4% of cases. The median number of EVT sessions was 2.5, and the mean interval from the index event to the first EVT session was 10.5 days. EVT achieved a 100% technical success rate, with no 30-day mortality; there was 1 in-hospital death (7.1%), 2 cases of stricture (14.3%), and 1 major bleeding event (7.1%). Adverse events were observed more frequently in patients who underwent ≥3 EVT sessions (57.1%) compared with those who underwent <3 sessions, in whom no adverse events occurred.Conclusion: This study suggests that EVT is a safe and effective treatment for gastrointestinal transmural defects, with high technical success rates. The number of EVT sessions and the timing of treatment initiation appeared to be associated with complications and overall clinical outcomes.

  • Open Access

    Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team

    by Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, et al.

    Janus kinase (JAK) inhibitors are an important treatment option for ulcerative colitis, providing rapid onset of action, oral administration, and efficacy even after biologic failure. The 3 approved agents—tofacitinib, filgotinib, and upadacitinib—differ in JAK isoform selectivity, leading to clinically meaningful differences in efficacy and safety. Evidence from network meta-analyses, clinical trials, and real-world studies consistently shows that upadacitinib provides the highest efficacy for induction and maintenance of remission, whereas filgotinib demonstrates the most favorable safety profile. The strong efficacy of upadacitinib and tofacitinib is particularly relevant in patients with severe disease, including acute severe ulcerative colitis, and upadacitinib maintains high efficacy regardless of prior advanced therapy exposure. JAK inhibitors also benefit extraintestinal manifestations. Although risks such as herpes zoster, serious infection, thromboembolism, and major cardiovascular events differ among agents, long-term data suggest generally acceptable safety when used appropriately. Intraclass JAK-to-JAK cycling is feasible, with about half of patients achieving steroid-free clinical remission in retrospective cohorts. Based on mechanistic, clinical, and real-world evidence, filgotinib may be a first-line option for patients with lower disease activity or when safety is a priority, whereas upadacitinib or tofacitinib may be preferred in higher disease activity. Strategically selecting agents may improve durability and outcomes.


  • Open Access

    Practices and perceptions of 5-aminosalicylic acid use in Crohn’s disease: a nationwide survey of physicians in Korea by KASID Guidelines Taskforce Team

    by June Hwa Bae, Seung Yong Shin, Dong Hyun Kim, Seung Min Hong, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, et al.

    Background/Aims: Despite international guidelines recommending against the use of 5-aminosalicylic acid (5-ASA) for Crohn’s disease (CD), it remains widely prescribed. This study aimed to investigate current patterns of 5-ASA use and physicians’ perceptions of its efficacy among Korean specialists. Methods: A nationwide online survey was conducted in August 2025 targeting Korean gastroenterologists and colorectal surgeons managing inflammatory bowel disease. The questionnaire included 19 items addressing prescribing behaviors, perceived efficacy, and clinical decision-making regarding 5-ASA in CD. Results: A total of 118 out of 124 physicians (95.2%) responded to the survey. The majority (67.8%) reported prescribing 5-ASA to more than half of their patients with CD. Standard to high doses ( > 2 g/day) were commonly used (94.9%), and timedependent formulations were preferred (92.4%). Although 55.1% used 5-ASA irrespective of disease location, it was frequently prescribed for colonic/ileocolonic disease (57.7%). Physicians primarily used 5-ASA in cases of non-active or mildly active CD. Notably, over 70% of respondents perceived 5-ASA to have a marginal yet beneficial effect on clinical remission, biomarker improvement, and mucosal healing. Approximately one-third of physicians reported continuing 5-ASA even after initiating biologics or small molecules. Conclusions: This survey reveals a substantial gap between clinical guidelines and current practice in Korea regarding 5-ASA use for CD. Many physicians continue to view 5-ASA as a relevant option, particularly for patients with low inflammatory burden. These discrepancies likely reflect practical factors such as clinical experience and drug characteristics, which should be carefully considered before excluding 5-ASA from CD management.


  • Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study

    by Eun Mi Song, Hyung-Mi An, Seong-Eun Kim, Ki-Nam Shim, Hye-Kyung Jung, Sung-Ae Jung, Chang Mo Moon

    Background: The role of biologics and small molecules in coronavirus disease 2019 (COVID-19) risk remains unclear. Therefore, we aimed to evaluate COVID-19 risk among patients with systemic autoimmune diseases treated with biologics or small molecules using the population-based cohort in Korea. Methods: We compared COVID-19 risk in 46 639 patients treated with biologics or small molecules (biologics group) to a 1:2 propensity score–matched (PSM) group of 86 980 controls (nonbiologics group). We matched the groups based on age, sex, type of autoimmune disease, Charlson Comorbidity Index, concurrent medications, and pre-COVID-19 vaccine doses. Results: After PSM, the biologics group exhibited a significantly higher COVID-19 risk (adjusted odds ratio [aOR], 1.20 [95% confidence interval {CI}, 1.08–1.34]) than the nonbiologics group. Subgroup analysis revealed a significant increase in COVID-19 risk in the biologics group that received suboptimal vaccines (aOR, 1.20 [95% CI, 1.08–1.34]). However, under optimal vaccine administration (3–4 doses), the risk of COVID-19 did not differ significantly between the biologics and nonbiologics groups (aOR, 1.22 [95% CI, .74–2.00]). Furthermore, COVID-19 risk significantly increased in patients with anti–tumor necrosis factor agents (aOR, 1.20 [95% CI, 1.05–1.36]), tofacitinib (aOR, 1.76 [95% CI, 1.15–2.71]), and abatacept (aOR, 1.98 [95% CI, 1.11–3.50]), compared with nonusers. Conclusions: Among patients with systemic autoimmune diseases, the risk of COVID-19 was significantly higher in those taking biologics or small molecules than in those not taking biologics. When receiving suboptimal COVID-19 vaccination, the risk of COVID-19 significantly increased in the biologics compared to the nonbiologics group, but it was mitigated through optimal vaccinations.


  • Open Access

    Enhancing the Predictions of Cytomegalovirus Infection in Severe Ulcerative Colitis Using a Deep Learning Ensemble Model: Development and Validation Study

    by Jeong Heon Kim, A Reum Choe, Ju Ran Byeon, Yehyun Park, Eun Mi Song, Seong-Eun Kim, Eui Sun Jeong, Rena Lee, Jin Sung Kim, So Hyun Ahn, et al.

    Background: Cytomegalovirus (CMV) reactivation in patients with severe ulcerative colitis (UC) leads to worse outcomes; yet, early detection remains challenging due to the reliance on time-intensive biopsy procedures. Objective: This study explores the use of deep learning to differentiate CMV from severe UC through endoscopic imaging, offering a potential noninvasive diagnostic tool. Methods: We analyzed 86 endoscopic images using an ensemble of deep learning models, including DenseNet (Densely Connected Convolutional Network) 121 pretrained on ImageNet. Advanced preprocessing and test-time augmentation (TTA) were applied to optimize model performance. The models were evaluated using metrics such as accuracy, precision, recall, F1-score, and area under the curve. Results: The ensemble approach, enhanced by TTA, achieved high performance, with an accuracy of 0.836, precision of 0.850, recall of 0.904, and an F1-score of 0.875. Models without TTA showed a significant drop in these metrics, emphasizing TTA’s importance in improving classification performance. Conclusions: This study demonstrates that deep learning models can effectively distinguish CMV from severe UC in endoscopic images, paving the way for early, noninvasive diagnosis and improved patient care.


  • Open Access

    Inflammatory transcriptomic signatures and cell type compositions in inflamed and non-inflamed colonic mucosa of ulcerative colitis

    by Eun Mi Song, Jahanzeb Saqib, Yang Hee Joo, Zehra Ramsha, Chang Mo Moon, Sung-Ae Jung, Junil Kim